Latuda Enters ‘Twilight’ Phase Pending Generic Competition
Lurasidone Launches Could Have Knock-On Effect On Caplyta Market
A swathe of generic lurasidone launches following the originator’s US patent expiry may trigger a shift in the antipsychotics space.
You may also be interested in...
Lupin has offered further specifics on expected FDA action for its proposed Spiriva generic, as the Indian firm reported a solid third financial quarter that saw an uptick in sales and profits, including turnover growth in the US.
The highly genericized bipolar disorder market is set for change as both new long-acting injectable formulations of older products and novel therapies reach the market, while firms like NRx and BioXcel target major unmet needs in a disease that needs more R&D.
Lupin has announced a number of drug approvals in the US, as well as a biosimilar partnership in the Middle East and the launch of a novel fixed-dose triple combination drug in its native Indian market.